This inventor holds 6 USPTO granted patents. Top assignees: The University of Texas System, Case Western Reserve University, Duke University. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:




Years Active: 2021-2025
Title: Innovations of Shelton S Bradrick
Introduction
Shelton S Bradrick is a notable inventor based in Galveston, Texas. He has made significant contributions to the field of medical therapies, particularly in the treatment of autoimmune diseases and cancer. With a total of six patents to his name, Bradrick's work focuses on innovative approaches to modulate the immune response.
Latest Patents
One of Bradrick's latest patents is centered around a soluble interleukin-7 receptor (SIL7R) modulating therapy. This invention includes compositions and methods for treating autoimmune disorders or cancers in subjects in need. The method involves administering an effective amount of a composition that comprises an oligonucleotide specifically binding to a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA. This influences the splicing of exon 6, thereby affecting the expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide can be an antisense oligonucleotide (ASO) or a splice-modulating antisense oligonucleotide (SM-ASO).
Career Highlights
Bradrick has worked with prestigious institutions such as the University of Texas System and Duke University. His career reflects a commitment to advancing medical science through innovative research and development.
Collaborations
Some of his notable coworkers include Mariano A Garcia-Blanco and Gaddiel Galarza-Munoz. Their collaborative efforts have contributed to the success of Bradrick's inventions.
Conclusion
Shelton S Bradrick's work exemplifies the impact of innovation in the medical field, particularly in developing therapies for complex diseases. His contributions continue to pave the way for future advancements in treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile